FDA greenlights Genentech’s eye implant for macular degeneration. Will it be a tough sell?
Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants.
That’s the stigma Genentech will potentially face as it attempts to con...
Continue Reading →
